1) Identify new biomarkers that predict treatment response and help to personalize decision-making to antiviral therapy in patients with chronic viral hepatitis
2) Identify new biomarkers that could predict disease progression and risk stratification in patients with non-malignant CLD
3) Identify new tumor markers for early diagnosis and predicting clinical outcome of patients with HCC and CCA
4) Elucidate new molecular mechanisms and biomarkers of HCC and CCA that could lead to the development of more effective anticancer therapy